


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Currently Amended)** A compound of formula I:



I


wherein, independently for each occurrence,

L is a bond or L is alkyl, alkenyl, or cycloalkyl which may be substituted with one or more R1;

A is a monocyclic ring of 4-7 atoms containing 0-2 heteroatoms, a bicyclic ring of 8-12 atoms containing 0-4 heteroatoms or a tricyclic ring of 12-16 atoms containing 0-6 heteroatoms wherein the rings are independently aliphatic, aromatic, heteroaryl, or heterocyclic; wherein the heteroatoms selected from N, S, and O, and wherein the rings are optionally substituted with one or more groups selected from C₁₋₄ alkyl, CH₂OH, OR'', SR'', CN, N(R'')₂, CH₂N(R'')₂, NO₂, CF₃, CO₂R'', CON(R'')₂, COR'', NR''C(O)R'', F, Cl, Br, I and -S(O)_tCF₃, wherein R'' is H, alkyl or alkaryl;

R₁ is, independently for each occurrence, H, alkyl, cycloalkyl, aryl, or alkaryl;


R₂ is



wherein the B adjacent to the D moiety, independently for each occurrence,

is selected from the group consisting of: a-bond, C(R₁)₂ or C=O;

D is, independently for each occurrence, selected from the group consisting of:



that the two Ds are different, and wherein for D, B is selected from the group consisting of a bond, C(R₁)₂ or C=O;

J is selected from the group consisting of NR₁, CH₂, CH₂CH₂, or O;

Q is N or CH;

r is 0, 1, or 2;

b is an integer from 0-4;


a is 0;

n is an integer from 0 to 4;


or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein L is a C₂ alkenyl.

3-4. (Canceled)



5. (Original) The compound of claim 1, wherein L is a C₂ alkenyl and R₂ is
wherein R₁ is H.



6. (Original) The compound of claim 1, wherein L is a C₂ alkenyl and R₂ is
wherein R₁ is H and the D adjacent to B is NR₁.

7-12. (Canceled)

13. **(Original)** The compound of claim 1, wherein A is a 9 membered bicyclic heteroaryl.

14. **(Original)** The compound of claim 1, wherein A comprises at least 1 heteroatom.

15-16. **(Canceled)**

17. **(Original)** The compound of claim 1, wherein A comprises at least 1 oxygen atom.

18.-23. **(Canceled)**

24. **(Original)** A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

25. **(Currently Amended)** The composition of claim 24, wherein the pharmaceutically acceptable carrier is suitable for intravenous or injectable [I.J] administration.

26.-30. **(Canceled)**

31. **(Previously Presented)** A tablet comprising the composition of claim 24, such that the amount of compound provided in 20 tablets, if taken together, provides a dose of at least the ED₅₀ but no more than ten times the ED₅₀.

32.-33. **(Canceled)**

34. **(Previously Presented)** A pill for reducing bacterial levels in a subject with a bacteria related illness, comprising a compound of claim 53.

35.-48. **(Canceled)**

49. **(Original)** A kit comprising the pharmaceutical composition of claim 24 and instructions for use thereof.

50. **(Previously Presented)** The compound of claim 6, wherein B is CH₂.

51. **(Previously Presented)** The compound of claim 50, wherein A comprises a nine-membered bicyclic heteroaryl comprising at least one O.

52. **(Canceled)**

53. **(Previously Presented)** The compound (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, or pharmaceutically acceptable salts thereof.

54. **(Previously Presented)** A pharmaceutically acceptable composition comprising the compound of claim 53, and a pharmaceutically acceptable carrier.